High-resolution fiber-optic ultrasonic "CT" assists in full-lifecycle analysis of lithium battery health evolution
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Jun-2025 14:10 ET (21-Jun-2025 18:10 GMT/UTC)
In recent years, with the rapid development of the new energy vehicle industry, the endurance and energy density of lithium batteries have been significantly improved. However, this advancement has correspondingly increased the risks associated with battery failures. Consequently, implementing safety failure analysis and early warning mechanisms for lithium batteries has become critically important. Conducting dynamic analysis of the entire lifecycle process – including encapsulation, electrolyte filling, charging/discharging, and damage – can effectively guide battery manufacturing and usage practices, thereby advancing next-generation battery development.
Current battery health monitoring methodologies encompass solutions such as radiography, thermal imaging, ultrasonic testing, and internal stress detection. Among these, ultrasound technology stands out as an exceptionally suitable "CT" imaging tool for lithium batteries due to its superior penetration capability, rapid response speed, high spatial resolution, and real-time monitoring capacity, which enable distinct responses to various internal evolution processes. Notably, fiber-optic ultrasound solutions, in particular, offer miniaturization, high sensitivity, resolution, and penetration depth, positioning them as a promising technology for battery diagnostics.
Ulrich Steidl, M.D., Ph.D., professor and chair of cell biology at Albert Einstein College of Medicine and deputy director at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center, has been elected a member of the Association of American Physicians (AAP), a prestigious 140-year-old honorary society dedicated to advancing medical knowledge through basic and clinical science.
Researchers at the University of California San Diego School of Medicine have found that individuals with colon cancer and a documented history of high cannabis use were more than 20 times more likely to die within five years of diagnosis compared to those without such a history.